{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:59Z","timestamp":1781953439242,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijrobp.2023.04.025","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T01:29:49Z","timestamp":1683336589000},"page":"321-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2\/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-201X","authenticated-orcid":false,"given":"Gabriella","family":"Macchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1169","authenticated-orcid":false,"given":"Donato","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Laliscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Fodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Draghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliana","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ferioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Titone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Balcet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Di Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vicenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Giuseppe","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.04.025_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0003","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.3390\/cancers14174176","article-title":"Recurrent endometrial cancer: Which is the best treatment? Systematic review of the literature","volume":"14","author":"Restaino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ijgc-2021-002466","article-title":"Role of stereotactic body radiotherapy in gynecologic radiation oncology","volume":"32","author":"Shenker","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0006","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0008","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation versus stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0009","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0012","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","article-title":"Immunological mechanisms responsible for radiation-induced abscopal effect","volume":"39","author":"Rodr\u00edguez-Ruiz","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0013","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0041-1731576","article-title":"CyberKnife stereotactic ablative radiotherapy for recurrent or oligometastatic gynecological cancers","volume":"10","author":"Kataria","year":"2021","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/IGC.0000000000000869","article-title":"Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies","volume":"27","author":"Mesko","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fonc.2012.00181","article-title":"Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies","volume":"2","author":"Kunos","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/07357907.2020.1817483","article-title":"Stereotactic body radiation therapy in oligometastatic uterine cancer: Clinical outcomes and toxicity","volume":"38","author":"Reddy","year":"2020","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0018","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): A collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0019","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ijgc-2021-003237","article-title":"Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2\/RAD study): A collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0022","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events v.4.03 (CTCAE v.4.03)"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0023","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s00432-020-03223-9","article-title":"Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases","volume":"146","author":"Nicosia","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0024","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: A step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12672-022-00540-y","article-title":"Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: A sharp tool to prolong the interval of systemic treatment","volume":"13","author":"Shen","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0026","first-page":"5103","article-title":"Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: A cooperative study of the Korean Radiation Oncology Group (KROG 14-11)","volume":"35","author":"Park","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0027","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijrobp.2008.07.020","article-title":"Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer","volume":"74","author":"Choi","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euf.2017.07.006","article-title":"Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: A systematic review of the role of stereotactic body radiotherapy","volume":"3","author":"Ponti","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0029","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2019.03.255","article-title":"Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?","volume":"154","author":"Lee","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0031","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","article-title":"The role of stereotactic ablative body radiotherapy in gynaecological cancers: A systematic review","volume":"29","author":"Mendez","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0032","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2020.08.010","article-title":"Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review","volume":"159","author":"Yegya-Raman","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.025_bib0033","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/IGC.0000000000000885","article-title":"Clinical outcomes of stereotactic body radiotherapy in oligometastatic gynecological cancer","volume":"27","author":"Laliscia","year":"2017","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623004170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T12:03:00Z","timestamp":1725105780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623004170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0360301623004170"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.025","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2\/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}